ATE423551T1 - Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält - Google Patents

Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält

Info

Publication number
ATE423551T1
ATE423551T1 AT04760495T AT04760495T ATE423551T1 AT E423551 T1 ATE423551 T1 AT E423551T1 AT 04760495 T AT04760495 T AT 04760495T AT 04760495 T AT04760495 T AT 04760495T AT E423551 T1 ATE423551 T1 AT E423551T1
Authority
AT
Austria
Prior art keywords
active ingredient
dosage form
agent component
adverse
abuse
Prior art date
Application number
AT04760495T
Other languages
German (de)
English (en)
Inventor
John R Hart
Steven C Anderson
Melissa A Vanblaricom
Ellen R Bosl
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Application granted granted Critical
Publication of ATE423551T1 publication Critical patent/ATE423551T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04760495T 2003-04-30 2004-03-23 Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält ATE423551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46724303P 2003-04-30 2003-04-30
US10/744,966 US20040219195A1 (en) 2003-04-30 2003-12-23 Abuse-resistant transdermal dosage form

Publications (1)

Publication Number Publication Date
ATE423551T1 true ATE423551T1 (de) 2009-03-15

Family

ID=33313652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04760495T ATE423551T1 (de) 2003-04-30 2004-03-23 Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält

Country Status (9)

Country Link
US (2) US20040219195A1 (enExample)
EP (1) EP1651196B1 (enExample)
JP (2) JP2006525315A (enExample)
AT (1) ATE423551T1 (enExample)
AU (2) AU2004237579A1 (enExample)
CA (1) CA2523709A1 (enExample)
DE (1) DE602004019653D1 (enExample)
ES (1) ES2322154T3 (enExample)
WO (1) WO2004098568A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
EP1641441B1 (en) 2003-04-30 2014-03-12 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
JP2008543768A (ja) 2005-06-10 2008-12-04 スリーエム イノベイティブ プロパティズ カンパニー 接着性積層体区画を取り扱うための方法
AU2006326377B2 (en) * 2005-12-13 2010-10-07 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
DE102006025282A1 (de) * 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
WO2008073576A1 (en) * 2006-12-08 2008-06-19 Alcon, Inc. Drug delivery device
JP2011513287A (ja) * 2008-02-28 2011-04-28 シントロファーマ リミテッド 医薬品組成物
JP5386205B2 (ja) * 2009-03-19 2014-01-15 リンテック株式会社 経皮吸収型貼付剤
WO2011123180A1 (en) * 2010-04-03 2011-10-06 Praful Doshi Medical devices including medicaments and methods of making and using same
EA033256B1 (ru) 2011-08-18 2019-09-30 Байоделивери Сайенсиз Интернэшнл, Инк. Не вызывающие зависимость двухслойные устройства для трансмукозальной доставки бупренорфина
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2013148506A1 (en) * 2012-03-30 2013-10-03 3M Innovative Properties Company Urea-based and urethane-based pressure sensitive adhesive blends
US9950106B2 (en) 2012-12-05 2018-04-24 Cook Medical Technologies Llc Antimicrobial barrier device
LT3096746T (lt) 2014-01-22 2019-06-10 4P Therapeutics Transderminės sistemos, leidžiančios išvengti piktnaudžiavimo vaistais ir netinkamo vaistų vartojimo
EP3233492B1 (en) 2014-12-18 2021-11-10 Kindeva Drug Delivery L.P. Methods of handling adhesive laminate patches
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
EP3247262A1 (en) 2015-01-23 2017-11-29 Marcio Marc Abreu Apparatus and method for skin treatment
CN110470607B (zh) * 2018-05-09 2021-12-07 江苏集萃智能液晶科技有限公司 一种检测混合溶液中亲水性有机溶剂含量的方法
WO2020008370A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1602344A (en) * 1924-01-09 1926-10-05 Eagle Peter Medicating compress
US2807262A (en) * 1952-12-10 1957-09-24 Robert B Lew Perforated plastic adhesive tape bandage
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4539256A (en) * 1982-09-09 1985-09-03 Minnesota Mining And Manufacturing Co. Microporous sheet material, method of making and articles made therewith
US4693776A (en) * 1985-05-16 1987-09-15 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
JPH0538010Y2 (enExample) * 1987-03-17 1993-09-27
KR970008118B1 (ko) * 1987-07-09 1997-05-21 엘테에스 로오만 테라피-지스테메 게엠베하 운트 콤파니 카게 피부 침투성 치료 시스템
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5176917A (en) * 1989-03-15 1993-01-05 Lts Lohmann Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
WO1995011945A1 (en) * 1993-10-29 1995-05-04 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesives having microstructured surfaces
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
AU6657396A (en) * 1995-07-28 1997-02-26 Novartis Ag Transdermal system
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
ATE364380T1 (de) * 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
WO2002087482A1 (en) * 2001-05-01 2002-11-07 Euro-Celtique Abuse resistant opioid containing transdermal systems
MXPA04010612A (es) * 2002-04-23 2005-07-14 Alza Corp Sistemas analgesicos transdermicos con potencial reducido de abuso.
SI1530469T1 (sl) * 2002-08-20 2009-06-30 Euro Celtique Sa Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
EP1641441B1 (en) * 2003-04-30 2014-03-12 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE102004038179A1 (de) * 2004-08-06 2006-03-16 Daimlerchrysler Ag Verfahren zur Herstellung einer thermisch beschichteten Zylinderlauffläche mit einer Einfuhrfase

Also Published As

Publication number Publication date
DE602004019653D1 (de) 2009-04-09
US20100068249A1 (en) 2010-03-18
WO2004098568A2 (en) 2004-11-18
WO2004098568A3 (en) 2005-02-03
JP2006525315A (ja) 2006-11-09
AU2010257440B2 (en) 2011-11-24
CA2523709A1 (en) 2004-11-18
AU2004237579A1 (en) 2004-11-18
AU2010257440A1 (en) 2011-01-20
JP2012140453A (ja) 2012-07-26
EP1651196B1 (en) 2009-02-25
US20040219195A1 (en) 2004-11-04
EP1651196A2 (en) 2006-05-03
ES2322154T3 (es) 2009-06-17

Similar Documents

Publication Publication Date Title
ATE423551T1 (de) Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält
CY1109070T1 (el) Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
DK2062573T3 (da) Misbrugsresistent opioid indeholdende transdermale systemer
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
DE69532751D1 (de) Kosmetische, pharmazeutische oder dermatologische Zusammensetzung, sowie die Zusammensetzung Alpha-TNFAntagonisten enthaltend
ATE380807T1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
RU2004103746A (ru) Фармацевтическая композиция для лечения интерстициального цистита
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
AR038858A1 (es) Combinacion
SE0103276D0 (sv) Anordning för administrering av salva till en hudyta
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
WO2005117871A3 (en) Pharmaceutical compositions for the treatment of pruritus
Cao et al. Efficacy of a topical proteinase-activated receptor-2 inhibitor on cowhage-induced pruritus: a randomized placebo-controlled double-blind study.
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties